Bolt Biotherapeutics (BOLT) Competitors $0.51 -0.01 (-1.61%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends BOLT vs. AGEN, FBIO, SABS, CRIS, MTEM, AMGN, GILD, VRTX, REGN, and ALNYShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Agenus Fortress Biotech SAB Biotherapeutics Curis Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Bolt Biotherapeutics (NASDAQ:BOLT) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking. Which has more volatility & risk, BOLT or AGEN? Bolt Biotherapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Do analysts rate BOLT or AGEN? Bolt Biotherapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 582.79%. Agenus has a consensus target price of $10.00, suggesting a potential upside of 187.36%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is BOLT or AGEN more profitable? Agenus has a net margin of -145.89% compared to Bolt Biotherapeutics' net margin of -665.56%. Agenus' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics-665.56% -69.46% -48.55% Agenus -145.89%N/A -85.68% Does the MarketBeat Community favor BOLT or AGEN? Agenus received 387 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 69.29% of users gave Agenus an outperform vote while only 64.52% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformBolt BiotherapeuticsOutperform Votes8064.52% Underperform Votes4435.48% AgenusOutperform Votes46769.29% Underperform Votes20730.71% Which has better earnings & valuation, BOLT or AGEN? Bolt Biotherapeutics has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.88M2.49-$69.20M-$1.71-0.30Agenus$156.31M0.52-$245.76M-$11.24-0.31 Do insiders & institutionals believe in BOLT or AGEN? 86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 4.6% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer BOLT or AGEN? In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Agenus. MarketBeat recorded 1 mentions for Bolt Biotherapeutics and 0 mentions for Agenus. Agenus' average media sentiment score of 1.00 beat Bolt Biotherapeutics' score of -0.33 indicating that Agenus is being referred to more favorably in the news media. Company Overall Sentiment Bolt Biotherapeutics Neutral Agenus Positive SummaryBolt Biotherapeutics and Agenus tied by winning 9 of the 18 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.62M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.309.9189.4217.36Price / Sales2.49309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book0.176.055.314.79Net Income-$69.20M$154.90M$122.54M$225.00M7 Day Performance-0.47%1.35%1.42%2.37%1 Month Performance2.52%0.41%2.51%4.40%1 Year Performance-54.23%3.08%25.30%20.10% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.9954 of 5 stars$0.51-1.6%$3.50+582.8%-54.2%$19.62M$7.88M-0.3090AGENAgenus3.9015 of 5 stars$3.16+1.3%$10.00+216.5%-69.9%$74.13M$160.43M-0.28440News CoveragePositive NewsGap UpFBIOFortress Biotech2.7397 of 5 stars$1.97-3.0%$13.67+593.7%-1.6%$54.38M$62.50M-0.65170Short Interest ↑Gap UpSABSSAB Biotherapeutics3.4358 of 5 stars$3.66-4.7%$12.40+238.8%-41.2%$33.78M$2.24M0.00140CRISCuris2.3645 of 5 stars$3.36-0.9%$23.00+584.5%-71.7%$28.45M$10.26M-0.4360MTEMMolecular Templates1.9691 of 5 stars$0.04+46.7%N/A-99.9%$248,000.00$23.48M-0.01260Positive NewsAMGNAmgen4.8826 of 5 stars$270.19+3.0%$314.91+16.6%-11.6%$145.24B$32.53B34.6026,700Positive NewsGap UpGILDGilead Sciences4.4621 of 5 stars$89.94+0.1%$97.96+8.9%+5.2%$112.09B$28.30B999.3318,000Short Interest ↑Analyst RevisionPositive NewsVRTXVertex Pharmaceuticals4.2809 of 5 stars$413.37+0.9%$490.38+18.6%-3.0%$106.45B$10.63B-207.725,400REGNRegeneron Pharmaceuticals4.5942 of 5 stars$716.90+2.9%$1,037.33+44.7%-27.0%$78.78B$13.85B17.7411,900ALNYAlnylam Pharmaceuticals4.4398 of 5 stars$258.27+8.5%$298.61+15.6%+33.8%$33.31B$2.09B-98.582,100High Trading Volume Related Companies and Tools Related Companies Agenus Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Molecular Templates Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLT Stock Alerts